Xilio Therapeutics, Inc. (XLO)
After hours:
| Previous close | 1.2300 |
| Open | 1.2200 |
| Bid | 1.2300 x 100 |
| Ask | 1.2900 x 400 |
| Day's range | 1.2000 - 1.2800 |
| 52-week range | 0.4900 - 3.4000 |
| Volume | |
| Avg. volume | 1,206,804 |
| Market cap | 47.248M |
| Beta (5Y monthly) | -0.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.7800 |
| Earnings date | 01 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.50 |
ZacksXilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
GlobeNewswireXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and commercialize XTX301, a tumor-activated IL-12 Anticipates cash runway into the second quarter of 2025 WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnolo
- GlobeNewswire
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and leveraging the company’s promising research platform for tumor-activated bispecific and cell engager moleculesReports additional Phase 2 data for XTX202, a tumor-activated, beta-gamma biased IL-2, supporting potential as combination therapy; plans to discontinue monotherapy development and evaluate
